You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OP…

Article info

Article menu

Download PDFPDF

XML
Rheumatology
Protocol
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)

Authors

  • Line Uhrenholt Department of Rheumatology, Aalborg University Hospital, Aalborg, DenmarkMusculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Annette Schlemmer Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark PubMed articlesGoogle scholar articles
  • Ellen-Margrethe Hauge Department of Rheumatology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • Robin Christensen Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, DenmarkResearch Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark PubMed articlesGoogle scholar articles
  • Lene Dreyer Department of Rheumatology, Aalborg University Hospital, Aalborg, DenmarkDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark PubMed articlesGoogle scholar articles
  • Maria E Suarez-Almazor Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Salome Kristensen Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Salome Kristensen; sakr{at}rn.dk
View Full Text

Citation

Uhrenholt L, Schlemmer A, Hauge E, et al
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
BMJ Open 2019;9:e028517. doi: 10.1136/bmjopen-2018-028517

Publication history

  • Received December 11, 2018
  • Revised May 16, 2019
  • Accepted June 14, 2019
  • First published July 9, 2019.
Online issue publication 
July 09, 2019
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.